OUR VISION: COMBINING TO CURE WITH BEST-IN-CLASS CANCER THERAPIES COWEN HEALTHCARE CONFERENCE MARCH 2, 2021 NYSE: RCUS Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding future events or results contained in this presentation are forward-looking statements, including statements ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38419 Arcus Biosciences, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47 ...

Pipeline and Strategy - Arcus Biosciences has an advanced pipeline targeting TIGIT, Adenosine, and PD-1 pathways[7] - Domvanalimab (anti-TIGIT mAb) is rapidly advancing in randomized combinations[7] - Zimberelimab (anti-PD-1 mAb) enables portfolio combination strategies with a clear path to commercialization[7] - Arcus is uniquely positioned with intra-portfolio combinations not available to other companies[7] Financial Position and Collaboration - Arcus Biosciences has over $825 million in cash[7] - The Gilead collaboration provides resources and expertise to exploit multiple intraportfolio opportunities[7] Clinical Development and Milestones - Preliminary randomized data from ongoing trials are expected in multiple settings and combinations[7] - Interim analysis of Domvanalimab and Zimberelimab in 1L NSCLC (ARC-7) is expected in the first half of 2021[24] - Preliminary Phase 1/1b data for AB680 in 1L PDAC (ARC-8) is expected in Q1 2021[24] Clinical Activity - In late-line mCRC, Etruma + mFOLFOX-6 showed a disease control rate (DCR) of 76%[57] - In patients with 3L+ mCRC, Etruma + mFOLFOX-6 showed a DCR of 64%[57]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3898 ...

OUR VISION: COMBINING TO CURE WITH BEST-IN-CLASS CANCER THERAPIES NYSE: RCUS JUNE 2020 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements about our vision, strategy, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 FORM 10-Q (Mark One) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ 3928 Point Eden Way Hayward, CA 94545 (Address of principal executive offices) Registrant's telephone number, including area cod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38419 Arcus Biosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-3898435 ( State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Registrant' ...

CREATING INNOVATIVE CANCER THERAPIES BY LEVERAGING UNDEREXPLOITED BIOLOGICAL OPPORTUNITIES September 2019 NYSE: RCUS FORWARD-LOOKING STATEMENTS/SAFE HARBOR This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statemen ...